[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Jeffrey Statland\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":44},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":29,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100571518","phase-1-clenbuterol-to-target-dux4-in-fshd-100571518",false,"NCT06721299","Clenbuterol to Target DUX4 in FSHD","Clenbuterol to Target DUX4 in FSHD (Target FSHD): Open Label Safety and Tolerability Study of 3 Doses of Clenbuterol","Target FSHD","Inclusion Criteria:\n\n* Genetically confirmed diagnosis of FSHD type 1 or 2, or have a clinical diagnosis of FSHD type 1 with a first degree relative with confirmed mutation\n* between 18 and 75 years of age\n* with a clinical severity score between 0 and 10\n* Able to walk 30ft without support of another person\n* Showing anti-gravity strength on at least one of the tibialis anterior muscles or having an MRI eligible muscle in the leg for needle biopsy\n* willing and able to provide informed consent\n* agree to follow the contraceptive requirement for duration of the study\n\nExclusion Criteria:\n\n* Pregnant or planning to become pregnant during the conduct of the study\n* have a poorly controlled medical condition\n* Were involved in a study of an experimental agent within 3 months of enrollment\n* Are taking beta-blockers or anabolic agent or potassium wasting diuretics\n* Are taking or are planning to take a GLP-1 Agonist during trial\n* have any condition or contraindication which would interfere with testing or preclude use of beta-agonist\n* Are taking blood thinners or medications which make a needle muscle biopsy contra-indicated\n* Has contraindication to lactose such as galactosmia, lactase deficiency and glucose-galactose malabsorption. For those who are lactose intolerant, the PI will determine acceptability based on tolerance reaction to lactose\n* Are taking any medications or therapies with a contraindication to Clenbuterol","ALL","18 Years","75 Years",{"count":21,"type":22},30,"ESTIMATED","INTERVENTIONAL",[25],"PHASE1","The purpose of this study is to determine if Clenbuterol is a therapeutic option for FSHD by determining the safety and tolerability of the medication at three different dose levels.",[28],"Muscular Dystrophy, Facioscapulohumeral",[30],"FSHD","RECRUITING","2026-02-24",{"date":34,"type":35},"2026-02-25","ACTUAL",{"date":37,"type":35},"2025-06-25",{"date":39,"type":22},"2028-07",{"name":41,"class":42},"Jeffrey Statland","OTHER",3,""]